Pulmonx
Narinder has more than 20 years of experience in taking medical devices through clinical development, regulatory approvals, and post-approval support through Medical Affairs’ activities, with 15 years of experience in interventional pulmonology. Prior to Pulmonx, Narinder was Vice President, Clinical Strategy and Medical Affairs–Pulmonary at Boston Scientific, where he played a key global role supporting the Alair® Bronchial Thermoplasty System. Previously, Narinder served as Vice President, Clinical Affairs at Asthmatx, where his efforts led to the approval of the first therapeutic device in the interventional pulmonology space. Earlier in his career, Narinder worked with Baxter following its acquisition of Fusion Medical Technologies, Nycomed Salutar, and Scios Inc. Narinder holds a PhD in Nutrition/Biochemistry from the University of Southampton, England, and completed his post-doctoral training jointly at the University of Southern California School of Medicine and School of Pharmacy.
This person is not in any offices
Pulmonx
2 followers
Pulmonx has developed the Zephyr Endobronchial Valve, a minimally invasive treatment for COPD/emphysema. The one-time procedure is done by bronchoscopy and requires no cutting or incisions. During the procedure, on average 4 tiny valves are placed in the airways to block off the diseased parts of the lung which allows trapped air to escape until the lobe is reduced. Reducing hyperinflation allows the healthier parts of the lungs to expand and take in more air. This results in patients being able to breathe easier and have less shortness of breath.1